Patents by Inventor Ursula Pettersson

Ursula Pettersson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7459463
    Abstract: The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6 -dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: December 2, 2008
    Assignee: AstraZeneca AB
    Inventors: Lars Lilljequist, Maria Lindkvist, Peter Nordberg, Ursula Pettersson, Tesfai Sebhatu
  • Publication number: 20070112021
    Abstract: The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.
    Type: Application
    Filed: December 16, 2004
    Publication date: May 17, 2007
    Applicant: TRAZENECA AB
    Inventors: Lars Lilljequist, Maria Lindkvist, Peter Nordberg, Ursula Pettersson, Tesfai Sebhatu
  • Publication number: 20060287249
    Abstract: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid slate stability when compared to amorphous forms of the compound.
    Type: Application
    Filed: August 22, 2006
    Publication date: December 21, 2006
    Applicant: AstraZeneca AB
    Inventors: Daniel Edvardsson, Lena Hedstrom, Anita Lundblad, Ursula Pettersson
  • Publication number: 20050153901
    Abstract: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Application
    Filed: March 11, 2005
    Publication date: July 14, 2005
    Applicant: AstraZeneca AB
    Inventors: Daniel Edvardsson, Lena Hedstrom, Anita Lundblad, Ursula Pettersson
  • Patent number: 6888007
    Abstract: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: May 3, 2005
    Assignee: AstraZeneca AB
    Inventors: Daniel Edvardsson, Lena Hedstróm, Anita Lundblad, Ursula Pettersson
  • Publication number: 20050054579
    Abstract: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Application
    Filed: May 20, 2002
    Publication date: March 10, 2005
    Inventors: Daniel Edvardsson, Lena Hedstrom, Anita Lundblad, Ursula Pettersson
  • Publication number: 20030017992
    Abstract: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Application
    Filed: May 20, 2002
    Publication date: January 23, 2003
    Applicant: AstraZeneca AB
    Inventors: Daniel Edvardsson, Lena Hedstrom, Anita Lundblad, Ursula Pettersson
  • Patent number: 6440939
    Abstract: There is provided EtO2C—CH2—(R)Cgl—Aze—Pab—OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl—Aze—Pab—OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: August 27, 2002
    Assignee: AstraZeneca AB
    Inventors: Daniel Edvardsson, Lena Hedström, Anita Lundblad, Ursula Pettersson
  • Publication number: 20010023244
    Abstract: There is provided EtO2C—CH2—(R)Cgl—Aze—Pab—OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl—Aze—Pab—OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Application
    Filed: January 4, 2001
    Publication date: September 20, 2001
    Applicant: Astra Aktiebolag
    Inventors: Daniel Edvardsson, Lena Hedstrom, Anita Lundblad, Ursula Pettersson
  • Patent number: 6225287
    Abstract: There is provided EtO2C—CH2—(R)Cgl—Aze—Pab—OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl—Aze—Pab—OH have a high chemical and solid state stability when compared to amorphous forms of the compound.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: May 1, 2001
    Assignee: Astra Aktiebolag
    Inventors: Daniel Edvardsson, Lena Hedström, Anita Lundblad, Ursula Pettersson